Entero Therapeutics, Inc. (NASDAQ:ENTO) Short Interest Up 127.7% in September

Entero Therapeutics, Inc. (NASDAQ:ENTO) was the target of a large increase in short interest during the month of September. As of September 30th, there was short interest totaling 172,600 shares, an increase of 127.7% from the September 15th total of 75,800 shares. Based on an average daily trading volume, of 1,770,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 11.7% of the company’s stock are short sold. Currently, 11.7% of the company’s stock are short sold. Based on an average daily trading volume, of 1,770,000 shares, the days-to-cover ratio is presently 0.1 days.

Entero Therapeutics Price Performance

ENTO stock opened at $4.96 on Monday. Entero Therapeutics has a 1-year low of $0.97 and a 1-year high of $5.84. The business’s 50 day simple moving average is $3.48 and its 200 day simple moving average is $2.06.

Entero Therapeutics (NASDAQ:ENTO) last posted its earnings results on Thursday, August 14th. The company reported ($0.42) earnings per share for the quarter.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Entero Therapeutics in a research report on Tuesday, October 14th. Wall Street Zen raised Entero Therapeutics to a “hold” rating in a research report on Friday, October 3rd. One analyst has rated the stock with a Sell rating, According to MarketBeat, Entero Therapeutics currently has a consensus rating of “Sell”.

About Entero Therapeutics

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.